Contact
Please use this form to send email to PR contact of this press release:
Aegis Therapeutics Announces Use of Intravail® in a Positive Phase 2 Study of DFN-02 for Acute Migraine
TO:
Please use this form to send email to PR contact of this press release:
Aegis Therapeutics Announces Use of Intravail® in a Positive Phase 2 Study of DFN-02 for Acute Migraine
TO: